Laurus Labs Share Price in Focus After Q4 Profit Jumps 3x to ₹234 Crore, Revenue Rises 19%

Laurus Labs reported a significant increase in net profit for the fourth quarter of FY25, with profit rising three times to ₹234 crore, compared to ₹76 crore in the same period last year. The growth was driven by strong sales across its business segments.

Revenue Sees Consistent Growth

The company’s revenue for the March quarter rose to ₹1,720 crore, up from ₹1,440 crore in Q4 FY24, reflecting steady demand and business expansion.

Read More, ACC Share Price Drops Over 3% After Q4 Profit Slips 20% Despite 13% Sales Surge; FY25 Revenue Up 5.6%. 

Full-Year Performance (FY25)

For the entire financial year, Laurus Labs posted:

• Net Profit: ₹358 crore (compared to ₹161 crore in FY24)

• Revenue: ₹5,554 crore (up from ₹5,041 crore in FY24)

Founder and CEO Satyanarayana Chava stated that Laurus Labs continues its transformation journey, fueled by robust demand for its CDMO (Contract Development and Manufacturing Organisation) services. He emphasised the company’s efforts to deepen client relationships and expand its operational capacity.

Focus on Long-Term Growth and Diversification

Chava mentioned the company’s aim to evolve into a well-diversified CMO/CDMO firm, supported by a strong product pipeline and multiple technology platforms. CFO V V Ravi Kumar added that Laurus Labs is optimistic about future growth, with plans to ramp up new assets and maintain a sharp focus on operational efficiency.

Dividend Announcement

The board of directors approved a second interim dividend of ₹0.80 per equity share (face value ₹2 each) for FY25.

Stock Movement

As of April 25 at 11:13 AM IST, Laurus Labs share price were trading at ₹610.70, down 5.39%. The stock opened at ₹630.00 and touched a high of ₹643.35 and a low of ₹607.20 during the session. The company has a market capitalisation of ₹32,910 crore, with a price-to-earnings (P/E) ratio of 164.29 and a dividend yield of 0.13%. Over the past 52 weeks, the stock has hit a high of ₹660.90 and a low of ₹385.45.

Conclusion

Laurus Labs has demonstrated strong financial performance with sharp growth in both quarterly and annual profits, driven by robust demand in its CDMO business. Backed by strategic investments and a promising pipeline, the company remains confident about sustaining its momentum and delivering long-term value to stakeholders.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.                         

Investments in securities market are subject to market risks, read all the related documents carefully before investing.